Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Carcinoma, Non-Small-Cell Lung 8Neoplasms 7Melanoma 5Squamous Cell Carcinoma of Head and Neck 4Head and Neck Neoplasms 4Triple Negative Breast Neoplasms 3Colorectal Neoplasms 3Carcinoma, Renal Cell 3Solid Tumor, Adult 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Neoplasm Metastasis 2Bites and Stings 2Turcot syndrome 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Sarcoma 1Recurrence 1Rectal Neoplasms 1Oligoprogressive 1Multiple Myeloma 1Liver Neoplasms 1Kidney Neoplasms 1Histiocytoma, Malignant Fibrous 1First-line Advanced NSCLC Patients 1Esophageal Squamous Cell Carcinoma 1Endometrial Neoplasms 1Dermatofibrosarcoma 1Colonic Neoplasms 1

Interventions

pembrolizumab 6Proton Therapy 3spartalizumab 2Rosuvastatin Calcium 2Paclitaxel 2Immune Checkpoint Inhibitors 2Cetuximab 2toripalimab 1sotorasib 1peposertib 1osimertinib 1necitumumab 1mirdametinib 1leronlimab 1apatinib 1amivantamab 1abemaciclib 1Valganciclovir 1Trastuzumab 1Therapeutics 1Rifampin 1Radiotherapy 1PankoMab-GEX 1Panitumumab 1Midazolam 1Metformin 1MEK inhibitor I 1Jupiter 1JPT1 protein, human 1Itraconazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Solid Tumor, Adult × Immune Checkpoint Inhibitors × Clear all
NCT04020185 2024-12-11

Safety and Efficacy Study of IMSA101 in Refractory Malignancies

ImmuneSensor Therapeutics Inc.

Phase 1/2 Completed
40 enrolled 16 charts
Other solid neoplasm

Solid Tumor, Adult

NCT06026254 2024-11-18

A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial

ImmuneSensor Therapeutics Inc.

Phase 1 Active not recruiting
2 enrolled
Other solid neoplasm

Solid Tumor, Adult

Data powered by HemOnc (CC BY 4.0) Colophon âš¡